2-(tert-Butoxy)-4-methylpyridine | 57883-15-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(tert-Butoxy)-4-methylpyridine
• 英文别名: 4-methyl-2-[(2-methylpropan-2-yl)oxy]pyridine
• CAS: 57883-15-5
• 化学式: C₁₀H₁₅NO
• 分子量: 165.23
• InChiKey: JXHLMXJCENWTKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20140336190A1

  公开（公告）日：2014-11-13

  This application relates to chemical compounds which may act as inhibitors of; or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R 1a , R 1b , R 2 , R 2b , R 3 , R 4a , R 4b , and R 5 are described herein.

  这个应用涉及可能作为抑制剂的化合物；或者可能以其他方式调节溴结构域含蛋白的活性，包括溴结构域含蛋白4（BRD4），以及含有这些化合物的组合物和配方，以及使用和制备这些化合物的方法。化合物包括式（I）的化合物 其中R 1a ，R 1b ，R 2 ，R 2b ，R 3 ，R 4a ，R 4b 和R 5 如本文所述。
• TANK-BINDING KINASE INHIBITOR COMPOUNDS
  申请人：Du Zhimin

  公开号：US20150344473A1

  公开（公告）日：2015-12-03

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  公开具有以下式（I）的化合物及其使用和制备方法：
• SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Pfizer Inc.

  公开号：US20170348313A1

  公开（公告）日：2017-12-07

  Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
• CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
  申请人：NeuPharma, Inc.

  公开号：US20180072688A1

  公开（公告）日：2018-03-15

  Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
• BIARYLMETHYL HETEROCYCLES
  申请人：Universite de Montreal

  公开号：US20190202808A1

  公开（公告）日：2019-07-04

  The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.